# OnCo record nct02411448 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02411448/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02411448", "NCT02411448" ;
  schema:name "A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE"@en ;
  schema:alternateName "RELAY"@en ;
  schema:description "A phase 3 trial of Ramucirumab, Erlotinib, Gefitinib in non-small-cell lung cancer and small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02411448/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02411448> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2015-05-06" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct02411448-lancet-oncol-2019/>, <https://onco.cc/key-papers/paper-nct02411448-j-thorac-oncol-2025-update/> .